Difference between revisions of "Oropharyngeal cancer, HPV-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy") Tags: mobile edit mobile web edit |
|||
| Line 25: | Line 25: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
| − | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32779-X/fulltext Gillison et al. 2018 (RTOG 1016)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32779-X/fulltext Gillison et al. 2018 (RTOG 1016)] | ||
| Line 45: | Line 45: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
| − | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32752-1/fulltext Mehanna et al. 2018 (De-ESCALaTE HPV)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32752-1/fulltext Mehanna et al. 2018 (De-ESCALaTE HPV)] | ||
Revision as of 19:02, 13 June 2019
| Section editor | |
|---|---|
 |
Michael Gibson, MD, PhD Vanderbilt University Nashville, TN  mgibson21212 |
Note: this page has regimens which are specific to oropharyngeal cancer that is human papilloma virus (HPV) positive. Please see the head and neck cancer page for other regimens.
1 regimens on this page
2 variants on this page
|
All lines of therapy
Cisplatin & RT
| back to top |
RT: Radiation Therapy
Variant #1, 100 mg/m2 q3wk x 2
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Gillison et al. 2018 (RTOG 1016) | Phase III (C) | Cetuximab & RT | Seems to have superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
21-day cycle for 2 cycles
Radiotherapy
- Concurrent radiation therapy 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 6 times per week
6-week course
Variant #2, 100 mg/m2 q3wk x 3
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Mehanna et al. 2018 (De-ESCALaTE HPV) | Phase III (C) | Cetuximab & RT | Superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
21-day cycle for 3 cycles
Radiotherapy
- Concurrent radiation therapy 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 6 times per week
6-week course
References
- RTOG 1016: Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2018 Nov 15. [Epub ahead of print] link to original article contains protocol PubMed
- De-ESCALaTE HPV: Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2018 Nov 15. [Epub ahead of print] link to original article contains protocol PubMed